Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MiraBiologics growth hormone receptor agonist
- Development stage
- Preclinical
- Lead developer
- Mira Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
MiraBiologics' growth hormone receptor (GHR) agonist is an agonistic monoclonal antibody designed to activate the GHR signaling pathway, mimicking the physiological role of endogenous growth hormone. Developed using the company's proprietary MirAgonist™ platform, the antibody is engineered to induce receptor dimerization or clustering upon binding, thereby triggering downstream cascades such as the JAK2/STAT5 pathway. This mechanism is intended to promote longitudinal growth and regulate protein, lipid, and carbohydrate metabolism. As a monoclonal antibody, this candidate potentially offers a significantly longer half-life than recombinant human growth hormone (rhGH), which typically requires daily administration. This long-acting profile could allow for weekly or monthly dosing, potentially improving treatment adherence and outcomes for patients with growth hormone deficiency (GHD) and related conditions.
- Other names
- Growth hormone receptor agonistGHR agonist antibodyGrowth hormone receptor agonistic antibody
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on MiraBiologics growth hormone receptor agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiraBiologics growth hormone receptor agonist.